| Literature DB >> 31759342 |
Amira Hassan Bekhet1,2, Ahmed Ramadan Abdallah3, Horeya M Ismail2,4, Doaa M Genena5, Nermin A Osman5, Ayman El Khatib6, Rami Labib Abbas6.
Abstract
BACKGROUND: Physical exercise may be beneficial to breast cancer (BC) survivors. Here, we systematically summarized the effects of aerobic exercise in BC survivors. We conducted a systematic review of randomized controlled trials (RCTs).Entities:
Keywords: Aerobic exercise; Quality of Life; breast cancer; physical activity
Mesh:
Year: 2019 PMID: 31759342 PMCID: PMC7063018 DOI: 10.31557/APJCP.2019.20.11.3197
Source DB: PubMed Journal: Asian Pac J Cancer Prev ISSN: 1513-7368
Figure 1PRISMA Flow Diagram of Screening and Study Selection Process
Shows a Summary of the Design and Main Findings of Included Studies
| study ID | Population | Mean age (SD) | sample size | duration of treatment | Type of Exercise | intensity | frequency | Outcomes measured | Summary of results |
|---|---|---|---|---|---|---|---|---|---|
| Matthews 2007 | Stage I–III breast cancer | 51.3 (9.0) / 56.9 (12.3) | 22 / 14 | 12 weeks | Walking / Usual care | Moderate | *In the first 4 weeks, three times/week. | * Overall physical activity level measured by CHAMPS questionnaire (MET-h/week) and the actigraph. | * Intervention proved effective in increasing physical activity levels among breast cancer survivors. |
| Campbell 2017 | stage I-IIIA breast cancer | 53.2 (7.0) / 51.4 (5.1) | 10/9 | 24 weeks | Walking / usual lifestyle | Moderate-to-vigorous | 150 min/week of aerobic exercise + two 45-minute supervised sessions per week in a research gym + two additional 30 minute unsupervised home sessions | *Self-reported cognitive dysfunction and associated impact on quality of life measured by (FACT-Cog). | No statistically significant improvement in self-reported cognitive function and neuropsychological tests. |
| Roveda 2016 | NR | 55.2 (6.8) / 58.2 (6.4) | 19 / 21 | 3 months | Brisk walking | Moderate | 2 sessions of | *Anthropometric and Body Composition | aerobic PA has |
| Fairey 2005 | Stage I-IIIA breast cancer | 59 (5) / 58 (6) | 24 / 28 | 15 weeks | cycle ergometers / no activity | Moderate | 3 times per week | *Effect of PA on CRP | *PA had borderline significant effect on CRP |
| Thomas 2013 | Stage 0–111A breast cancer | 56.5 (9.8) / 55.1 (7.6) | 35 / 30 | 6 months | Walking / usual care | Moderate | *Three 15-minute sessions (week1) | Effect of aerobic exercise on metabolic syndrome prevalence | *In overweight or obese, physically inactive BCS |
| Murtezani 2014 | 53 ( 11) / 51( 11) | 30/32 | 10 week | Aerobic exercise(treadmills, stationary bicycles, and stairclimbing | Moderate | three times per week for 10 weeks | *-Anthropometric | Results revealed that 10 week of moderateintensity aerobic exercise program significantly improves QOL and physical functioning in breast cancer survivors | |
| study ID | Population | Mean age (SD) | sample size | duration of treatment | Type of Exercise | intensity | frequency | Outcomes measured | Summary of results |
| Carter 2016 | DCIS or stage I-IIIA breast cancer | 55(8) for all participants | 76/76 | 3 months | treadmill walking/usual care | Vigrous-Moderate | -goal of meeting ≥150 min of | -baseline and immediately postintervention | Lower rate-pressure product during submaximal walking was |
| Saarto 2012 | Histologically proven invasive breast cancer T1-4,N0-3,M0 | Mean age (range) | 263/237 | 12 months | supervised and home training | progressive vigorous exercise training | -supervised training: once a | Changes in quality of life (QoL) during the intervention measured by the | *The amount of physical |
| Segar 1998 | Any type of breast cancer surgery | 47.5(7.1)/61.8(8.1) | 16/8 | 10 weeks | Exercise group / Exercise plus Behavior / control group | =< 60 of age predicted maximum heart rate | a minimum 30 minutes/seesion, | *Exercise adherence | *women who exercised had signficantly less depression and state and anxiety over time compared to control |
| Jones 2012 | stage0 to IIIA | 56.4 (9.6)/ 55.4(7.6) | 36/32 | 6 months | Aerobic exercise/ usual care | moderate- intensity aerobic exercise | 150 minutes over 3 weeks | 1-Arthopometric | Results revealed that the moderate-intensity |
| study ID | Population | Mean age (SD) | sample size | duration of treatment | Type of Exercise | intensity | frequency | Outcomes measured | Summary of results |
| Tizdast 2016 | stage I-III breast cancer | 44.1(4.6) for all participants | continous exercise grpup(n=9), interval exercise group (n=9), control group(n=9) | 8 weeks | Continuous exercise group/ Interval exercise group/ control group | varied according to trainng schedule | three times per week | *Body weight, | *The highest reduction in weight, body fat percentage and adipose tissue and the highest increase in VO2 peak occurred in the interval exercise group. |
| Irwin 2008 | stage 0 (in situ) to stage IIIA breast cancer | 56.5 ( 9.5) /55.1 ( 7.7 ) | 37/38 | 6 months | Moderate | 150 min/wk. of supervised gym-based and home-based aerobic | 1-Arthopometric | Women in the exercise-intervention group increased their average pedometer steps by 1621 steps per day compared with a decrease of 60 steps per day among women in the usual-care group (P <.01). | |
| Irwin 2009 (1) | stage 0 to IIIA breast cancer | 56.4 ( 9.5) /55.6 (7.7) | 37/38 | 6 months | moderate-intensity aerobic exercise | 150 minutes per week | 1-Arthopometric | Moderate-intensity aerobic exercise, per week, used in the study is proved to be tolerated in breast cancer survivors and efficacious in decreasing levels of IGF-I and IGFBP-3. | |
| Irwin 2009 (2) | Stage 0–IIIA | 56.5 (9.5)/ 55.1( 7.7) | 37/38 | 6 months | Moderate | 150 min/week | 1-Arthopometric | Aerobic exercise, such as brisk walking, was associated with | |
| Latka 2009 | stage 0 to stage IIIA breast cancer | 56.5(9.5)/NR | 37/38 | 6 months | Moderate | exercise goal was 30 min of exercise 5 days/week for | *BMI | *Women with higherBMI, |
Shows Baseline-Characteristics of Included Studies Participants
| study | Study arm | Sample Size | Age | Disease stage (%) In situ Stage I Stage II | BMI | Weight (kg) | Menopausal status | Time since diagnosis | Ethnicity (%) | Pedometer average, steps/d | Physical activity |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Matthews 2007 | Experimental | 22 | 51.3 (9) | Stage I (59%) | 28.3 (4.9) | 74.9(14.5) | Post-menopausal | 0.9 | White 82% | 7,409.4 (2,791.1) | *By CHAMPS unit of MET-h/week: |
| control | 14 | 56.9 (12.3) | Stage I (64%) | 29.9 (7.1) | 78.9(20.3) | Post-menopausal | 0.7 | White86% | 5,939.00 | *By CHAMPS unit of MET-h/week: | |
| Campbell 2017 | Experimental | 10 | 53.2 (7) | Stage I: 0 | 26.3 (5.7) | 71.1 (15.9) | Post-menopausal | NR | NR | NR | (MET-hr./wk.) |
| control | 9 | 51.4 (5.1) | Stage I: 0 | 26.1 (5.5) | 66.6 (16.7) | Post-menopausal | NR | NR | NR | (MET-hr./wk.) | |
| Roveda 2016 | Experimental | 19 | 55.2 (6.8) | NR | 25.4 (3.8) | 67.1 (11.9) | Pre & post-menopausal | NR | NR | 9790.9 ± 2817.2 | physical activity level |
| control | 21 | 58.2 (6.4) | NR | 24.6 (3.4) | 64.5 (9.6) | Pre & post-menopausal | NR | NR | 11001.6 ± 3702.2 | physical activity level | |
| Fairey 2005 | Experimental | 24 | 59 (5) | Stage I (42%) | 29.4 (7.4) | 78.1 (20.4) | Post-menopausal | NR | NR | NR | fitness described in baseline values for peak oxygen consumption (ml/kg/min |
| control | 28 | 58 (6) | Stage I (39%) | 29.1 (6.1) | 79.4 (16.4) | Post-menopausal | NR | NR | NR | cardiopulmonary fitness described in baseline values for peak oxygen consumption (ml/kg/min) | |
| Thomas 2013 | Experimental | 35 | 56.5 (9.8) | In situ (11%) | 30.8 (5.9) | 82.1 (16.5) | Post-menopausal | 3.6 (2.2) | White 83% | NR | Physical activity questionnaire |
| control | 30 | 55.1 (7.6) | In situ (10%) | 29.4 (7.4) | 77.2 (20.4) | Post-menopausal | 3.3 (2.6) | White 90% | NR | Physical activity questionnaire | |
| Study arm | Sample Size | Age | Disease stage (%) In situ Stage I Stage II | BMI | Weight (kg) | Menopausal status | Time since diagnosis | Ethnicity (%) | Pedometer average, steps/d | Physical activity | |
| Experimental | 37 | 56.5 (9.5) | In situ -11% | 30.4 (6.0) | NR | Post-menopausal | 3.6 (2.2) | Non-Hispanic white 84% | 5145 (2,312) | -Physical Activity Questionnaire | |
| control | 38 | 55.1 (7.7) | In situ -11% | 30.1 (7.4) | NR | Post-menopausal | 3.3 (2.6) | Non-Hispanic white 84% | 5342 (2,744) | -Physical Activity Questionnaire | |
| Experimental | 37 | 56.5 (9.5) | In situ -11% | 30.57 (5.95) | 81.28 (16.98) | Post-menopausal | 3.6 (2.2) | Non-Hispanic white 84% | 5.145 (2.312) | -Physical Activity Questionnaire | |
| control | 38 | 55.1 (7.7) | In situ -11% | 29.74 (7.27) | 78.4 (20.01) | Post-menopausal | 3.3 (2.6) | Non-Hispanic white 84% | 5.342 (2.744) | -Physical Activity Questionnaire | |
| Experimental | 36 | 56.4 (9.5) | In situ -11% | 30.4 (6.0) | 81.0 (16.8) | Post-menopausal | 3.6 (2.2) | Non-Hispanic white 83% | 5,083 (2,312) | -Physical Activity Questionnaire | |
| control | 32 | 55.6 (7.7) | In situ -13% | 30.1 (7.4) | 79.3 (21.3) | Post-menopausal | 3.3 (2.6) | Non-Hispanic white 90% | 5,624 (2,744) | -Physical Activity questionnaire | |
| Experimental | 36 | 56.4 (9.6) | In situ -13% | 30.6 (6.0) | 81.3 (17.0) | Post-menopausal | 3.5 (2.1%) | Non-Hispanic white 83% | 5083 (2,313) | -Physical activity questionnaire | |
| control | 31 | 55.4 (7.6) | In situ -11% | 29.4 (7.3) | 77.3 (20.0) | Post-menopausal | 3.1 (2.4%) | Non-Hispanic white 87% | 5661 (2,740) | -Physical activity questionnaire | |
| Study arm | Sample Size | Age | Disease stage (%) In situ Stage I Stage II | BMI | Weight (kg) | Menopausal status | Time since diagnosis | Ethnicity (%) | Pedometer average, steps/d | Physical activity | |
| Experimental | 30 | 53 (11) | Stage I (33%) | 25.9 (2.8) | 74.0 (9.4) | NR | NR | NR | NR | physical | |
| Control | 32 | 51 (11) | Stage I (47%) | 26.0 (3.3) | 73.0 (10.5) | NR | NR | NR | NR | -physical | |
| Experimental | 37 | 56.5 (9.5) | In Situ 11% | 30.4 (6.0) | NR | Post-menopausal | 3.6 (2.2) | Non-Hispanic white 84% | 5.145 (2.312) | Physical Activity Questionnaire- | |
| control | 38 | 55.1 (7.7) | In situ 11% | 30.1 (7.4) | NR | Post-menopausal | 3.3 (2.6) | Non-Hispanic white 84% | 5.342 (2,744) | -Physical Activity Questionnaire | |
| Experimental | 76 | 55 (8) | NR | 29.8 (6.2) | 79.5 (17.1) | Pre & post-menopausal | 54.2 (54.6) | NR | NR | -Physical activity measured | |
| control | 76 | 55 (8) | NR | 29.8 (6.2) | 79.5 (17.1) | Pre & post-menopausal | 54.2 (54.6) | NR | NR | -Physical activity measured | |
| Experimental | 263 | MEAN (range) | NR | NR | NR | Pre & post-menopausal | NR | NR | NR | *Cardiorespiratory fitness was | |
| control | 237 | MEAN (range) | NR | NR | NR | Pre & post-menopausal | NR | NR | NR | *Cardiorespiratory fitness was | |
| Study arm | Sample Size | Age | Disease stage (%) In situ Stage I Stage II | BMI | Weight (kg) | Menopausal status | Time since diagnosis | Ethnicity (%) | Pedometer average, steps/d | Physical activity | |
| Experimental | 16 | 47.5 (7.1) | NR | NR | NR | NR | NR | white 70% | NR | NR | |
| control | 8 | 61.8 (8.1) | NR | NR | NR | NR | NR | white 88% | NR | NR | |
| Continuous | 9 | 44.1 (4.6) | NR | 30 (3.4) | 75.4 (10.9) | Post-menopausal | NR | NR | NR | NR | |
| Interval | 8 | 44.1 (4.6) | NR | 29.9 (2.8) | 75.4 (6.6) | Post-menopausal | NR | NR | NR | NR | |
| control | 6 | 44.1 (4.6) | NR | 30.9 (4.07) | 81.7 (12.3) | Post-menopausal | NR | NR | NR | NR |
Figure 2Risk of Bias Summary for Included Studies